Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has updated stakeholders on the status of its delayed interim financial statements, originally announced March 1, 2024. The Ontario Securities Commission has issued a management cease trade order that restricts company executives from trading shares until the filings are completed, though it does not impede shareholder transactions. Meanwhile, the company has successfully closed a private placement offering, raising CAD$1.9 million through the issuance of common shares.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
